TNF and COVID-19: A total of four clinical trials of infliximab (anti-TNF-α) (NCT04425538, NCT04734678, NCT04593940, NCT04344249) and two clinical trials with adalimumab, another anti-TNF-α antibody (ChiCTR2000030089, NCT04705844) are ongoing to evaluate its effects in COVID-19 (252).